Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 2/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.57 |
| ▸ | MEN1 | O00255 | 2/20 | 0.57 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | PKM | P14618 | 1/20 | 0.54 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.52 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.51 |
| ▸ | MGLL | Q99685 | 1/20 | 0.51 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.51 |
| ▸ | CCNK | O75909 | 2/20 | 0.50 |
| ▸ | CDK12 | Q9NYV4 | 2/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.48 |
| ▸ | CDK1 | P06493 | 1/20 | 0.48 |
| ▸ | CDK2 | P24941 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22542170 | 0.91 | KMT2A (0.65) | KDM1AKMT2AMEN1EPHX2ALDH1A1 | |
| SCHEMBL22184356 | 0.88 | PDK2 (0.52) | KDM1AKMT2AMEN1ALDH1A1PDK2 | |
| SCHEMBL14392680 | 0.88 | PDK2 (0.52) | KDM1AKMT2AMEN1ALDH1A1PDK2 | |
| SCHEMBL19226422 | 0.87 | PKM (0.56) | KDM1AKMT2AMEN1EPHX2ALDH1A1 | |
| SCHEMBL24477822 | 0.87 | KMT2A (0.56) | KDM1AKMT2AMEN1EPHX2ALDH1A1 | |
| SCHEMBL22859014 | 0.87 | POLB (0.54) | KDM1AKMT2AEPHX2PDK2HSD11B1 | |
| SCHEMBL1448240 | 0.87 | PDK2 (0.51) | KDM1AKMT2AMEN1EPHX2PDK2 | |
| SCHEMBL7881494 | 0.86 | EPHX1 (0.63) | KDM1AKMT2AMEN1EPHX2ALDH1A1 | |
| SCHEMBL2132882 | 0.86 | EPHX1 (0.63) | KDM1AKMT2AMEN1EPHX2ALDH1A1 | |
| SCHEMBL2132888 | 0.86 | EPHX1 (0.63) | KDM1AKMT2AMEN1EPHX2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE46511-E1 | Fused pyrimidine derivatives for inhibition of tyrosine kinase activity | HANMI SCIENCE CO., LTD. (KR) | 2017-08-15 | — | — | US | disclosed |
| US-20170226132-A1 | TRIAZOLOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2017-08-10 | — | — | US | disclosed |
| US-20160229868-A1 | NOVEL FUSED PYRIMIDINE DERIVATIVES FOR INHIBITION OF TYROSINE KINASE ACTIVITY | HANMI SCIENCE CO., LTD (KR) | 2016-08-11 | — | — | US | disclosed |
| US-20160185780-A1 | TRIAZOLOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2016-06-30 | — | — | US | disclosed |
| US-9345719-B2 | Fused pyrimidine derivatives for inhibition of tyrosine kinase activity | HANMI SCIENCE CO., LTD. (KR) | 2016-05-24 | — | — | US | disclosed |
| US-8957065-B2 | Fused pyrimidine derivatives for inhibition of tyrosine kinase activity | HANMI SCIENCE CO., LTD (KR) | 2015-02-17 | — | — | US | disclosed |
| US-20150045324-A1 | NOVEL FUSED PYRIMIDINE DERIVATIVES FOR INHIBITION OF TYROSINE KINASE ACTIVITY | HANMI SCIENCE CO., LTD (KR) | 2015-02-12 | — | — | US | disclosed |
| US-20130116213-A1 | NOVEL FUSED PYRIMIDINE DERIVATIVES FOR INHIBITION OF TYROSINE KINASE ACTIVITY | HANMI SCIENCE CO., LTD. (KR) | 2013-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160185780-A1 | TRIAZOLOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | ABL1, JAK2, JAK1 | KDM1A 1215/4885KMT2A 1797/4885MEN1 2118/4885 |
| US-20160229868-A1 | NOVEL FUSED PYRIMIDINE DERIVATIVES FOR INHIBITION OF TYROSINE KINASE ACTIVITY | LCK, LTK, FYN | KDM1A 2086/4885KMT2A 1857/4885MEN1 4259/4885 |
| US-20150045324-A1 | NOVEL FUSED PYRIMIDINE DERIVATIVES FOR INHIBITION OF TYROSINE KINASE ACTIVITY | LCK, FYN, TYK2 | KDM1A 2020/4885KMT2A 1823/4885MEN1 3929/4885 |
| US-20170226132-A1 | TRIAZOLOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | ABL1, JAK2, JAK1 | KDM1A 1215/4885KMT2A 1797/4885MEN1 2118/4885 |
| US-20130116213-A1 | NOVEL FUSED PYRIMIDINE DERIVATIVES FOR INHIBITION OF TYROSINE KINASE ACTIVITY | LCK, FYN, TYK2 | KDM1A 2020/4885KMT2A 1823/4885MEN1 3929/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.